Investigational Drug Fails As Standalone Mesothelioma Treatment, AstraZeneca Says
LONDON — The investigational drug Tremelimumab does not improve overall survival rates of mesothelioma patients when used alone, AstraZeneca announced Feb. 29....To view the full article, register now.
Already a subscriber? Click here to view full article